PF
TEVA icon

Phoenix Financial’s Teva Pharmaceuticals TEVA Stock Holding History

Phoenix Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.29B Buy
42,777,414
+1,690,283
+4% +$54.4M 12.21% 1
2025
Q4 		$1.28B Sell
41,087,131
-208,113
-0.5% -$5.13M 13.9% 1
2025
Q3 		$834M Buy
41,295,244
+3,533,800
+9% +$62.1M 10.17% 1
2025
Q2 		$633M Buy
37,761,444
+10,296,872
+37% +$166M 8.35% 1
2025
Q1 		$422M Buy
27,464,572
+6,252,030
+29% +$112M 6.46% 1
2024
Q4 		$468M Sell
21,212,542
-1,349,134
-6% -$24.5M 6.38% 2
2024
Q3 		$407M Sell
22,561,676
-2,860,920
-11% -$50.1M 6.01% 2
2024
Q2 		$413M Sell
25,422,596
-9,159,191
-26% -$141M 6.29% 2
2024
Q1 		$488M Buy
34,581,787
+198,595
+0.6% +$2.5M 6.74% 2
2023
Q4 		$404M Sell
34,383,192
-98,500
-0.3% -$920K 6.69% 2
2023
Q3 		$352M Buy
34,481,692
+778,282
+2% +$7.25M 6.44% 2
2023
Q2 		$254M Buy
33,703,410
+11,569,608
+52% +$93.8M 5.19% 1
2023
Q1 		$196M Sell
22,133,802
-24,749
-0.1% -$245K 4.38% 2
2022
Q4 		$202M Buy
22,158,551
+1,327,471
+6% +$11.6M 3.91% 4
2022
Q3 		$163M Buy
20,831,080
+2,301,291
+12% +$20.3M 3.59% 4
2022
Q2 		$139M Buy
18,529,789
+1,830,388
+11% +$15.9M 2.85% 5
2022
Q1 		$157M Buy
16,699,401
+1,513,100
+10% +$12.6M 2.64% 4
2021
Q4 		$122M Buy
15,186,301
+1,015,500
+7% +$9.17M 2.01% 8
2021
Q3 		$138M Buy
14,170,801
+2,620,800
+23% +$24.5M 2.39% 5
2021
Q2 		$114M Sell
11,550,001
-26,132
-0.2% -$277K 2.18% 4
2021
Q1 		$134M Buy
11,576,133
+2,952,046
+34% +$33.9M 3.02% 2
2020
Q4 		$83.1M Sell
8,624,087
-2,527,589
-23% -$24.2M 2.23% 2
2020
Q3 		$94.7M Sell
11,151,676
-532,913
-5% -$5.64M 3.96% 1
2020
Q2 		$137M Buy
11,684,589
+355,220
+3% +$4.02M 5.8% 1
2020
Q1 		$99.3M Buy
11,329,369
+4,729,800
+72% +$48.5M 5.03% 1
2019
Q4 		$64.2M Buy
6,599,569
+1,371,737
+26% +$12.2M 2.68% 2
2019
Q3 		$34.3M Buy
+5,227,832
New +$40.1M 1.63% 7

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Phoenix Financial's TEVA Position: Q1 2026 in Review

Phoenix Financial increased its Teva Pharmaceuticals (TEVA) stake by 4.1% in Q1 2026, buying an estimated $54.4M and bringing the position to 42,777,414 shares worth $1.29B. The position accounts for 12.21% of the portfolio, ranked #1.

Phoenix Financial first reported a position in TEVA in Q3 2019 and has held it in 27 quarters since. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Phoenix Financial held 42,777,414 shares of Teva Pharmaceuticals worth $1.29B as of Q1 2026.
  • Phoenix Financial bought 1,690,283 Teva Pharmaceuticals shares in Q1 2026, an estimated $54.4M.
  • Teva Pharmaceuticals made up 12.21% of Phoenix Financial's portfolio in Q1 2026, its #1 holding.
  • Phoenix Financial first reported a position in Teva Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Phoenix Financial's 13F filing for Q1 2026, filed 11 May 2026.